production of liposome formulated drugs has allowed their advance in the pharmaceutical industry. [3] [4] [5] In the advent of the use of genetic material (DNA, ribozymes, DNAzymes, aptamers, (antisense-) oligonucleotides, small interfering RNAs) as therapeutic molecules the development of delivery systems to target these molecules to cells or to target organs becomes increasingly important. In this field the liposomes, in particular lipid-DNA complexes termed lipoplexes (see below), compete with viral gene transfection systems. Nanoparticles, nanospheres, polymersomes, nanogels, micelles, dendrimers, and virosomes are other main types of nanocarrier systems used for drug delivery. [6] [7] [8] [9] [10] [11] As schematically shown in Fig. 1 , modern DDS including polymer-drug conjugates, liposomes, osmotic pumps, microchips, wafers, transdermal patches and other systems vary in their concepts, compositions, shapes, sizes, drug loading capacity as well as in their pharmacokinetic and organ distribution properties. 12 All DDS, however, pursue the aim of improving drug delivery for the benefit of the patient.
The major applications of DDS comprise drugs that possess non-ideal physico-chemical and pharmacological properties such as 1) Poor solubility; 2)
Tissue damage caused by unintentional extravasation of drugs; 3) Loss of drug activity following administration; 4) Unfavorable pharmacokinetic properties and poor biodistribution and 5) Lack of selectivity for target organs or tissues.
Systemic drug distribution may cause toxic side effects and low drug concentrations at target tissues; this could lead to suboptimal therapeutic effects. 11, [15] [16] [17] [18] [19] As schematically shown in Fig. 2 , the liposomes evolved from rather simple compositions ( Fig. 2A, B ) to highly sophisticated multi-component systems. The state-of-the-art liposomes used for parenteral drug delivery are the long circulating ("stealth") liposomes (Fig. 2C, D Various cell uptake mechanisms for liposomes have been described.
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Due to their particulate properties, phagocytic uptake mechanisms (phagocytose, endocytose, pinocytose) are predominant, however cell membrane adhesion and fusion can also occur. In the phagocytic uptake pathway liposomes are captured at the cell surface followed by endosomal and lysosomal uptake. This feature complicates CPP applications as target specific drug delivery systems; therefore therapeutic applications seem unlikely, unless their target cell specificity can be significantly improved. 
Liposomes as carriers of lipophilic
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